« Back

Russell Greig
Chairman, Non-Executive Director

Dr Russell Greig is Chairman of our board of directors and has been a member of the board since July 2018. With more than 35 years’ experience in the pharmaceutical and biotechnology industry, Dr Greig has extensive expertise in research and development, business development and commercial operations. Dr Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008, as well as serving on the GlaxoSmithKline corporate executive team. Currently, Dr Greig serves as the Chair of AM Pharma and MedEye Solutions (Netherlands), eTheRNA (Belgium), Horama (France) and Sanifit (Spain/US).
He was previously Chair of Ablynx (Belgium) prior to its acquisition by Sanofi in 2018, and as a NED of Tigenix (Belgium/Spain) prior to its pending acquisition by Takeda in 2018. Dr Greig was also Chair of Isconova (Sweden) acquired by Novavax (United States), Novagali (France) acquired by Santen (Japan), and Syntaxin (United Kingdom) acquired by Ipsen (France). He has served as a venture partner at Kurma Partners (France). Finally, Dr Greig was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland.

RSS FeedsFinancial Tear SheetE-mail PagePrint PageE-mail Alerts